Illumina Stakes A Claim In NIPT Market With $450-Million Acquisition Of Verinata
Gene-sequencing company Illumina has signed a definitive agreement to acquire Verinata Health for up to $450 million, staking its claim in the fast-growing, noninvasive prenatal genetic-testing market.
You may also be interested in...
Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.
Device companies kicked off 2013 by raising $1.1 billion via 45 transactions; the only device M&A transaction in Q1 to exceed the billion-dollar mark was Cardinal Health Inc.’s $2.07 billion acquisition of AssuraMed. Diagnostics firms began 2013 by raising a total of $286 million in the opening quarter, a 46% improvement over Q4 2012’s tally.